Your browser doesn't support javascript.
loading
Structural insights into the clustering and activation of Tie2 receptor mediated by Tie2 agonistic antibody.
Jo, Gyunghee; Bae, Jeomil; Hong, Ho Jeong; Han, Ah-Reum; Kim, Do-Kyun; Hong, Seon Pyo; Kim, Jung A; Lee, Sangkyu; Koh, Gou Young; Kim, Ho Min.
Afiliação
  • Jo G; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea.
  • Bae J; Center for Biomolecular & Cellular Structure, Institute for Basic Science (IBS), Daejeon, 34126, Republic of Korea.
  • Hong HJ; Center for Vascular Research, IBS, Daejeon, 34141, Republic of Korea.
  • Han AR; Center for Biomolecular & Cellular Structure, Institute for Basic Science (IBS), Daejeon, 34126, Republic of Korea.
  • Kim DK; Center for Biomolecular & Cellular Structure, Institute for Basic Science (IBS), Daejeon, 34126, Republic of Korea.
  • Hong SP; Center for Biomolecular & Cellular Structure, Institute for Basic Science (IBS), Daejeon, 34126, Republic of Korea.
  • Kim JA; Center for Vascular Research, IBS, Daejeon, 34141, Republic of Korea.
  • Lee S; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea.
  • Koh GY; Center for Cognition and Sociality, IBS, Daejeon, 34126, Republic of Korea.
  • Kim HM; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea. gykoh@kaist.ac.kr.
Nat Commun ; 12(1): 6287, 2021 11 01.
Article em En | MEDLINE | ID: mdl-34725372
Angiopoietin (Angpt)-Tie receptor 2 (Tie2) plays key roles in vascular development and homeostasis as well as pathological vascular remodeling. Therefore, Tie2-agonistic antibody and engineered Angpt1 variants have been developed as potential therapeutics for ischemic and inflammatory vascular diseases. However, their underlying mechanisms for Tie2 clustering and activation remain elusive and the poor manufacturability and stability of Angpt1 variants limit their clinical application. Here, we develop a human Tie2-agonistic antibody (hTAAB), which targets the membrane proximal fibronectin type III domain of Tie2 distinct from the Angpt-binding site. Our Tie2/hTAAB complex structures reveal that hTAAB tethers the preformed Tie2 homodimers into polygonal assemblies through specific binding to Tie2 Fn3 domain. Notably, the polygonal Tie2 clustering induced by hTAAB is critical for Tie2 activation and are resistant to antagonism by Angpt2. Our results provide insight into the molecular mechanism of Tie2 clustering and activation mediated by hTAAB, and the structure-based humanization of hTAAB creates a potential clinical application.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptor TIE-2 / Anticorpos Monoclonais Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptor TIE-2 / Anticorpos Monoclonais Idioma: En Ano de publicação: 2021 Tipo de documento: Article